ftInvstr

CORONA · Healthcare ₹2545.7 +0.45% Mkt Cap ₹15550 Cr overvalued

CORONA

Healthcare Drug Manufacturers - General

★ Watchlist ⧉ Add to bucket

₹2545.7

+0.45% today · 30d +25.71%

as of 2026-11-09

Price · Daily Candles

Detect candlestick pattern

AI narrative is temporarily unavailable for CORONA. The deterministic sections below render from live data.

₹ Latest Earnings · Q ending 2026-06-30

REVENUE

₹422 Cr

NET PROFIT

₹60 Cr

OPM

22.62%

EPS

₹9.83

PE 69.95

Intrinsic value · DCF ₹397.92 · Margin of safety -84.4% (overvalued) · FCF yield 0.36%

◇ Sector Position

PEERPEROCE %

CORONA69.9533.0

GLAXO40.0557.97

RUBICON90.2127.36

PFIZER20.9324.29

+ 2 more peers — sign in to view

ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

SCORE / 100

Overall

6-axis composite of the sections below.

Performance — —

Valuation STRETCHED 20

Growth STRONG 75

Profitability HIGH 88

Technicals NEUTRAL 65

Risk LOW 90

Key Stats

TTM PE

69.95

P/B

17.99

52W HIGH

₹2719.3

OFF HIGH

-6.38%

DIV YIELD

0.39%

MKT CAP

₹15550 Cr

◉ Active Signals

MACDBullish48.2046

RSI(14)Bearish79.0

Street Consensus

3 analysts

₹2361.33

mean target

Low ₹2260.0Now ₹2545.7High ₹2479.0

⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold CORONA and at what entry.